Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumretuzumab + Chemo in Squamous NSCLC
NCT02204345Phase 2Terminated
- Sponsor
- Roche
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of lumretuzumab in squamous cell carcinoma of the lung (SCCL), sponsored by Roche. Started Oct 2014; status: terminated.
02
Drugs
lumretuzumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02204345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204345.